{"id":584133,"date":"2026-06-05T00:00:00","date_gmt":"2026-06-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrhe0003-2026-biopharma-hemophilia-a-current-treatment-current-treatment-physician-insights-hemophilia-a-with\/"},"modified":"2026-06-05T00:00:00","modified_gmt":"2026-06-05T00:00:00","slug":"cutrhe0003-2026-biopharma-hemophilia-a-current-treatment-current-treatment-physician-insights-hemophilia-a-with","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrhe0003-2026-biopharma-hemophilia-a-current-treatment-current-treatment-physician-insights-hemophilia-a-with\/","title":{"rendered":"Hemophilia A &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Hemophilia A with Inhibitors (US)"},"content":{"rendered":"<p>Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management strategies. While bypassing agents such as FEIBA and NovoSeven have historically been the primary go-to therapies, the landscape has been transformed by the launch of Hemlibra, which has redefined the standard of care for prophylaxis. The hemophilia A inhibitor market is entering a new era of disruption with the introduction of Alhemo (concizumab) and Qfitlia (fitusiran), which promise to decrease treatment burdens. Furthermore, the potential for immune tolerance induction (<abbr title=\"immune tolerance induction\">ITI<\/abbr>) protocols to be used alongside novel non-factor therapies remains a critical, evolving discussion among hematologists. Understanding how hematologists navigate balancing bleed protection with the risks of thrombotic events and the high cost of care is vital for hemophilia A treatment. This report provides a comprehensive analysis of the hemophilia A inhibitor treatment landscape, with insights into the shifting treatment dynamics.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How are current treatment patterns evolving for hemophilia A patients with inhibitors across the United States?<\/li>\n<li>How do factors such as mode of drug administration, drug delivery, or formulary access influence choice of therapy?<\/li>\n<li>How is patient share distributed among leading therapies, and how stable are these patterns over time?<\/li>\n<li>What will be the impact of novel agents such as Qfitlia and Alhemo for the hemophilia A with inhibitors market?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<p>Geographies: United States.<\/p>\n<p>Primary research: Survey of 101 hematologists.<\/p>\n<p>Key drugs covered: Hemlibra, Alhemo, Qfitlia, Factor VIII replacement therapies, FEIBA, NovoSeven, Sevenfact.<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul>\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<li>Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-584133","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematology","biopharma-therapy-areas-hemophilia","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/584133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":0,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/584133\/revisions"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=584133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}